Back

Understanding MAC with Jennifer Faber- Gerling

December 2024

In this episode, Corinne Young interviews Jennifer Faber- Gerling about mycobacterium avian complex (MAC). They discuss the bacterium itself, the rise in cases, screening and diagnosis, treatment and side effects, reinfection versus reactivation, and symptom management. Jennifer emphasized the importance of close surveillance, collaboration with a multidisciplinary team, and individualized care for patients with MAC.

Related Podcasts

ILD 101, ILD 102, ILD Peds

July 2025

20:57 m

Join Jessica Glennie, APRN, Naomi Miyazawa, PA-C, and Cori Fratelli, FNP, from the 2025 APAPP National Conference as they explore pediatric and adult interstitial lung disease (ILD). This episode covers diagnosis, disease progression, anti-inflammatory and anti-fibrotic therapies, and the importance of multidisciplinary care. Learn about pediatric ILD (CHILD), autoimmune-related ILD, and new treatment guidelines—all through real-world clinical insights.

Immunology of the Lung Podcast

July 2025

11:40 m

Tune in from the Annual APAPP National Conference for a dynamic episode of the APAPP Podcast featuring Corinne Young, FNP-C, Amanda Michaud, PA-C, and Brian Bizik, PA-C—three expert APPs leading engaging sessions on lung immunology, rare immune deficiencies, and COPD updates. Amanda breaks down the “Immunology of the Lung 101” and her “Finding the Zebras” series, where she highlights key red flags for primary immune deficiencies, sharing real patient cases and diagnostic tips to help clinicians recognize and manage these commonly missed conditions. Brian shares practical takeaways from the latest GOLD COPD guidelines, including how biomarkers like eosinophil counts can guide personalized inhaled corticosteroid decisions. Whether you're managing patients with asthma, COPD, or unexplained recurrent infections, this episode delivers clinical pearls you can apply in your practice right away. Discover why this APP-led meeting stands out as a must-attend event for pulmonary and immunology providers. Be sure to like, subscribe, and follow us for more expert-driven conversations.

How To Differentiate ILD Progression vs Treatment Failure

July 2026

25:23 m

In this episode of the ILD Community Network Podcast, host Amanda Mixon, PA-C, is joined by Jenny Williams, PA-C, for a practical discussion on how clinicians can differentiate interstitial lung disease progression from treatment failure. Together, they explore the clinical, physiologic, and radiographic clues that may signal progressive pulmonary fibrosis, including worsening shortness of breath, cough, declining FVC or DLCO, increased oxygen needs, and high-resolution CT findings such as worsening fibrosis, traction bronchiectasis, honeycombing, and volume loss. This episode also highlights the importance of ruling out other causes of respiratory symptoms, including pulmonary hypertension, cardiac disease, pulmonary embolism, anemia, deconditioning, reflux, aspiration, and infection, before determining whether a patient’s current ILD therapy is no longer working. Listeners will gain practical insights into pulmonary function test monitoring, imaging follow-up, treatment escalation, anti-fibrotic therapy, multidisciplinary collaboration, and referral to ILD specialty centers to help improve long-term outcomes for patients living with interstitial lung disease.

Deep Dive Into ILD Therapeutics

December 2024

37:59 m

Check out this podcast recording from the 2024 APAPP Conference in Vegas!

Idiopathic Shortness of Breath part 2 Dysfunctional Breathing Clinic

December 2024

29:41 m

Nurse practitioner Cori Fratelli from National Jewish Health discusses breathing pattern disorders, related to unexplained dyspnea. Cori advocates to consider these disorders, discusses treatment methods like breath retraining, inspiratory muscle training, and emphasizes the need for more research and specialized clinics.

Advancing ILD & PH-ILD Care

July 2025

21:35 m

Join Jessica Glennie, APRN, and Lori Reed, FNP, from the 2025 APAPP National Conference as they discuss key insights in diagnosing and managing interstitial lung disease (ILD) and pulmonary hypertension (PH). From interpreting PFTs and recognizing red flags to exploring current and emerging therapies like inhaled treprostinil and neuredomast, this episode offers practical strategies for improving patient care. Tune in for expert tips and updates every pulmonary provider should know.

Evolving IPF Care: The Significance of Nerandomilast’s FDA Approval

October 2025

25:20 m

In this special crossover episode, host Amanda Mixon, PA-C, President of RhAPP, sits down with Corinne Young, FNP-C, founder and President of the Association of Pulmonary Advanced Practice Providers (APAPP), to discuss one of the most exciting developments in interstitial lung disease: the FDA approval of nerandomilast for idiopathic pulmonary fibrosis (IPF). This breakthrough marks the first new IPF therapy in more than a decade and introduces a novel PDE4B mechanism of action designed to reduce fibrosis and improve lung function. Together, Amanda and Corrine unpack the clinical data behind nerandomilast, key findings from the FIBRONEER-IPF trial, and how its safety profile—particularly reduced GI side effects—may reshape treatment pathways and patient quality of life. The conversation also highlights the overlap between rheumatology and pulmonology in managing fibrotic lung diseases and the importance of interdisciplinary collaboration as additional indications for progressive pulmonary fibrosis (PPF) are anticipated. #Rheumatology #Pulmonology #InterstitialLungDisease #IPF #Nerandomilast #Fibrosis #AdvancedPracticeProviders #APPs #FDAApproval #ClinicalUpdates

Podcast: Recognizing PH-ILD Earlier: Missed Signals, Delayed Diagnosis, and How to Close the Gap

February 2026

31:14 m

Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is one of the most impactful—and often underrecognized—complications in patients with established ILD, frequently presenting with symptoms that mimic ILD progression. In this ILD Community Network podcast episode, Amanda Mixon is joined by Corinne Young to break down why PH-ILD is missed, what red flags clinicians should watch for, and when to escalate evaluation beyond “worsening ILD.” The discussion highlights practical screening cues such as disproportionate DLCO decline, stable imaging with worsening dyspnea, enlarged pulmonary arteries on high-resolution CT, and revealing echocardiogram findings including RV/RA enlargement, TAPSE, and tricuspid regurgitation—along with the limitations of echo estimates and the role of right heart catheterization for confirmation. Tune in for real-world strategies to improve earlier recognition, reduce diagnostic delays, and strengthen multidisciplinary collaboration between rheumatology, pulmonology, and primary care to improve outcomes for patients living with ILD and PH-ILD. #InterstitialLungDisease #PulmonaryHypertension #PHILD #Rheumatology #Pulmonology #AdvancedPracticeProviders #MedicalEducation #ILDCommunityNetwork #APAPP #RhAPP

The Role of APPs in Advanced ILD/PH ILD

August 2026

18:12 m

In this ILD Community Network podcast episode, host Kelsey Cramer is joined by Jenny Williams, for a practical discussion on the role of advanced practice providers in advanced interstitial lung disease and pulmonary hypertension associated with interstitial lung disease, also known as PH-ILD. Together, they explore how APPs can recognize high-risk signs of disease progression, including worsening shortness of breath, declining exercise tolerance, increasing oxygen needs, changes in pulmonary function tests, reduced six-minute walk distance, and signs of right heart strain or pulmonary hypertension. This episode also highlights when clinicians should consider referral to ILD specialty centers, pulmonary hypertension clinics, lung transplant evaluation, pulmonary rehab, anti-fibrotic therapy, inhaled therapy for PH-ILD, and palliative care support. Listeners will gain practical insights into identifying advanced ILD, understanding PH-ILD risk factors, recognizing transplant referral triggers, coordinating multidisciplinary care, and ensuring patients receive timely access to specialized treatment and advanced therapies.

Idiopathic Shortness of Breath Part 1 Using CPET

December 2024

26:37 m

National Jewish Health’s NP, Cori Fratelli, shares with us how she and her colleagues utilize CPET and other testing in patients with unexplained shortness of breath.